4Basebio

4Basebio Equity

The The Equity of 4Basebio (4BB.L) as of Oct 21, 2026 is 10.11 M GBP. In the previous year, The Equity was 26.38 M GBP — a change of -61.67% (lower).

Equity

10.11 MGBP

YoY

-61.67%

Last updated:

In 2025, 4Basebio's equity was 10.11 M GBP, a -61.67% increase from the 26.38 M GBP equity in the previous year.

The 4Basebio Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
-1.89 M GBP
Jan 1, 2020
15.46 M GBP
Jan 1, 2021
11.70 M GBP
Jan 1, 2022
7.12 M GBP
Jan 1, 2023
-492,000.00 GBP
Jan 1, 2024
26.38 M GBP
Jan 1, 2025
10.11 M GBP
The 4Basebio Equity history
YEAREquityYoY
10.11 MGBP-61.67%
26.38 MGBP-5,461.79%
-492,000.00GBP-106.91%
7.12 MGBP-39.12%
11.70 MGBP-24.34%
15.46 MGBP-917.88%
-1.89 MGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

4Basebio Stock analysis

What does 4Basebio do? 4basebio Plc develops advanced therapy medicinal products using synthetic DNA and non-viral delivery platforms for cell and gene therapies, DNA vaccines, and mRNA solutions. The company manufactures application-specific synthetic DNA for research, therapeutic, and pharmacological use, while also creating non-viral vectors for efficient payload delivery. Its technology enables the production of synthetic DNA constructs, mRNA, and vectors for cell and tissue-specific delivery, targeting applications such as AAV and Lentivirus viral vectors, mRNA vaccines, genome editing, and DNA vaccines. The company focuses on exploiting intellectual property in cell and gene therapies and DNA vaccines to drive innovation and commercialization. The primary customers for 4basebio Plc's products include research institutions, biotechnology firms, and pharmaceutical companies seeking advanced therapeutic solutions. These entities purchase synthetic DNA constructs, non-viral delivery vectors, and specialized DNA-based products for use in developing cell and gene therapies, DNA vaccines, and mRNA therapeutics. The company's offerings are tailored to support the development of safe and effective treatments across multiple therapeutic areas. 4basebio Plc's revenue streams are derived from the manufacturing and supply of synthetic DNA products, non-viral delivery platforms, and intellectual property licensing. The company generates income through the sale of application-specific synthetic DNA for research and therapeutic applications, as well as the development of delivery vectors for targeted therapies. By leveraging its proprietary technology in DNA synthesis and payload delivery, 4basebio Plc positions itself as a key provider of essential components for next-generation biologics and vaccines. 4Basebio is one of the most popular companies on Eulerpool.

Equity Details

Analyzing 4Basebio's Equity

4Basebio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding 4Basebio's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating 4Basebio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

4Basebio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in 4Basebio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about 4Basebio stock

The Equity of 4Basebio is 10.11 M GBP in 2025.

The Equity of 4Basebio changed from 26.38 M GBP to 10.11 M GBP, representing a -61.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity 4Basebio since 2006 – with annual values, charts, and detailed analysis.

The Equity's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's 4Basebio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — 4Basebio

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — 4Basebio